Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type i prolongs survival in mice bearing established syngeneic intracranial malignant glioma

Neurosurgery

Volumn 71, Issue 3, 2012, Pages 741-748

  Barnard, Zachary ^a   Wakimoto, Hiroaki ^a   Zaupa, Cecile ^a   Patel, Anoop P ^a   Klehm, Jacquelyn ^a   Martuza, Robert L ^a   Rabkin, Samuel D ^a   Curry, William T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Brain tumor; Flt3 ligand; Glioma; Herpes; Immunotherapy; Oncolytic virus; Vaccine

Indexed keywords

FLT3 LIGAND; ONCOLYTIC HERPES VIRUS; ONCOLYTIC HERPES VIRUS TYPE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; IMMUNOCOMPETENCE; KAPLAN MEIER METHOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; TREATMENT OUTCOME; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DISEASE MODELS, ANIMAL; FMS-LIKE TYROSINE KINASE 3; GLIOMA; HERPESVIRUS 1, HUMAN; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; TRANSPLANTATION, ISOGENEIC;

EID: 84865762787     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318260fd73     Document Type: Article

References (46)

1. Kim W, Liau LM. Dendritic cell vaccines for brain tumors. Neurosurg Clin N Am. 2010;21(1):139-157.
2. Kanaly CW, Ding D, Heimberger AB, Sampson JH. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am. 2010;21(1): 95-109.
3. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7(10):867-874.
4. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009;17(1):199-207.
5. Fong Y, Kim T, Bhargava A, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther. 2009;17(2):389-394.
6. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737-6747.
7. Agarwalla PK, Barnard ZR, Curry WT Jr. Virally mediated immunotherapy for brain tumors. Neurosurg Clin N Am. 2010;21(1):167-179.
8. Rainov NG, Zimmer C, Chase M, et al. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther. 1995;6(12):1543-1552.
9. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 1999;10(17):2741-2755.
10. Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res. 2006;12(9):2919-2927.
11. Farrell CJ, Zaupa C, Barnard Z, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008;14(23):7711-7716.
12. Lapteva N, Aldrich M, Rollins L, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009;17(9): 1626-1636.
13. Lapteva N, Aldrich M, Weksberg D, et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 2009;32(2):145-156.
14. Drexler HG, Quentmeier H. FLT3: receptor and ligand. Growth Factors. 2004;22 (2):71-73.
15. Lyman SD, James L, Escobar S, et al. Identification of soluble and membranebound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene. 1995;10(1):149-157.
16. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001;98(11):6396-6401.
17. Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res. 2005;65(23):10663-10668.
18. Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol. 2006;6:40.
19. Martínez-Murillo R, Martínez A. Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. HistolHistopathol. 2007;22(12):1309-1326.
20. Seyfried TN, el-Abbadi M, Roy ML. Ganglioside distribution in murine neural tumors. Mol Chem Neuropathol. 1992;17(2):147-167.
21. Maguire CA, Meijer DH, LeRoy SG, et al. Preventing growth of brain tumors by creating a zone of resistance. Mol Ther. 2008;16(10):1695-1702.
22. Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD81 cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A. 1996;93(19):10399-10404.
23. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res. 2005;65(4): 1532-1540.
24. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69(8):3472-3481.
25. Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res. 2006;12(2): 643-652.
26. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184(5):1953-1962.
27. Naik SH, Sathe P, Park HY, et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol. 2007;8(11):1217-1226.
28. Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther. 2002;1(5):486-489.
29. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med. 1997;3(6):625-631.
30. Chakravarty PK, Alfieri A, Thomas EK, et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 1999;59(24):6028-6032.
31. Morse MA, Nair S, Fernandez-Casal M, et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol. 2000;18(23):3883-3893.
32. Marroquin CE, Westwood JA, Lapointe R, et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother. 2002;25(3):278-288.
33. Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009;69(19):7747-7755.
34. Song S, Liu C, Wang J, et al. Vaccination with combination of Fit3L and RANTES in a DNA prime-protein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine. 2009;27(7):1111-1118.
35. CrittendenM,GoughM,Harrington K,Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003;63(17):5505-5512.
36. Saito T, Takayama T, Osaki T, et al. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity. Cancer Sci. 2008;99(10):2028-2036.
37. Edukulla R, Ramakrishna E, Woller N, et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerasedependent oncolytic viruses. Cancer Res. 2009;69(4):1448-1458.
38. Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther. 2004; 10(6):1071-1084.
39. Curtin JF, King GD, Barcia C, et al. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol. 2006;176(6):3566-3577.
40. Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005;65(16):7194-7204.
41. Ghulam Muhammad AK, Candolfi M, King GD, et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res. 2009;15 (19):6113-6127.
42. Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6(1):e10.
43. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol. 2005;26(7): 381-387.
44. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol. 2007;81(1):84-91.
45. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replicationcompetent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol. 2000;74(8):3832-3841.
46. Todo T, Feigenbaum F, Rabkin SD, et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther. 2000;2(6):588-595.